{"id":691169,"date":"2022-10-03T08:33:32","date_gmt":"2022-10-03T12:33:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/"},"modified":"2022-10-03T08:33:32","modified_gmt":"2022-10-03T12:33:32","slug":"zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/","title":{"rendered":"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day<\/b><\/p>\n<p>VANCOUVER, British Columbia &amp; SEATTLE&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nZymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Stifel 2022 Healthcare Conference<\/b>. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15<sup>th<\/sup> \u2013 16<sup>th<\/sup> in New York, NY.\n<\/li>\n<li><b>Jefferies London Healthcare Conference<\/b>. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15<sup>th<\/sup> \u2013 17<sup>th<\/sup> in London, United Kingdom.\n<\/li>\n<\/ul>\n<p>\nIn addition, Zymeworks will present an update on its preclinical research programs at an <b>Early R&amp;D day on October 20<sup>th<\/sup>, 2022, in New York, NY<\/b>. At this event, led by Paul Moore, PhD, Zymeworks\u2019 Chief Scientific Officer, we plan to present data from multiple preclinical product candidates built upon our industry-leading multispecific and next-generation TOPO1i based ADC platforms as well as an update to our future scientific vision.\n<\/p>\n<p>\nAll presentations and webcasts will be available on Zymeworks\u2019 website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fir.zymeworks.com%2Fevents-and-presentations&amp;esheet=52934263&amp;newsitemid=20221003005320&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.zymeworks.com%2Fevents-and-presentations&amp;index=1&amp;md5=714ba42d18731a80f9cb03cdaec49afe\">http:\/\/ir.zymeworks.com\/events-and-presentations<\/a>.\n<\/p>\n<p><b>About Zymeworks Inc.<\/b><\/p>\n<p>\nZymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks\u2019 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks\u2019 lead clinical candidate, zanidatamab, is a novel Azymetric\u2122 HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks\u2019 second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2 \u2011targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks\u2019 proprietary ZymeLink\u2122 linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zymeworksclinicaltrials.com%2F&amp;esheet=52934263&amp;newsitemid=20221003005320&amp;lan=en-US&amp;anchor=www.zymeworksclinicaltrials.com&amp;index=2&amp;md5=e7421b7280564589b46cba59e20f1597\">www.zymeworksclinicaltrials.com<\/a>. For additional information about Zymeworks, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zymeworks.com%2F&amp;esheet=52934263&amp;newsitemid=20221003005320&amp;lan=en-US&amp;anchor=www.zymeworks.com&amp;index=3&amp;md5=b2e745621cd406fb321d3a8ff9862bc6\">www.zymeworks.com<\/a> and follow <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FZymeworksInc&amp;esheet=52934263&amp;newsitemid=20221003005320&amp;lan=en-US&amp;anchor=%40ZymeworksInc&amp;index=4&amp;md5=8e5bd18118fb2459e5d6abd070588b6f\">@ZymeworksInc<\/a> on Twitter.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20221003005320\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20221003005320\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Inquiries:<br \/>\n<br \/>Jack Spinks<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@zymeworks.com\">ir@zymeworks.com<br \/>\n<\/a><\/p>\n<p>Media Inquiries:<br \/>\n<br \/>Diana Papove<br \/>\n<br \/>(604) 678-1388<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@zymeworks.com\">media@zymeworks.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America United States United Kingdom Europe Canada Washington New York<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221003005320\/en\/183056\/3\/Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day VANCOUVER, British Columbia &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: Stifel 2022 Healthcare Conference. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15th \u2013 16th in New York, NY. Jefferies London Healthcare Conference. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15th \u2013 17th in London, United Kingdom. In addition, Zymeworks will present an update on its preclinical research programs at an Early R&amp;D day on October 20th, 2022, in New York, NY. At this event, led by Paul Moore, PhD, Zymeworks\u2019 Chief &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-691169","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day VANCOUVER, British Columbia &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: Stifel 2022 Healthcare Conference. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15th \u2013 16th in New York, NY. Jefferies London Healthcare Conference. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15th \u2013 17th in London, United Kingdom. In addition, Zymeworks will present an update on its preclinical research programs at an Early R&amp;D day on October 20th, 2022, in New York, NY. At this event, led by Paul Moore, PhD, Zymeworks\u2019 Chief &hellip; Continue reading &quot;Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T12:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day\",\"datePublished\":\"2022-10-03T12:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/\"},\"wordCount\":408,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/\",\"name\":\"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2022-10-03T12:33:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/","og_locale":"en_US","og_type":"article","og_title":"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day - Market Newsdesk","og_description":"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day VANCOUVER, British Columbia &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211; Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences: Stifel 2022 Healthcare Conference. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15th \u2013 16th in New York, NY. Jefferies London Healthcare Conference. Zymeworks\u2019 management will participate in one-on-one meetings and present on November 15th \u2013 17th in London, United Kingdom. In addition, Zymeworks will present an update on its preclinical research programs at an Early R&amp;D day on October 20th, 2022, in New York, NY. At this event, led by Paul Moore, PhD, Zymeworks\u2019 Chief &hellip; Continue reading \"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-03T12:33:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day","datePublished":"2022-10-03T12:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/"},"wordCount":408,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/","name":"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2022-10-03T12:33:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20221003005320r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-participation-in-upcoming-investor-conferences-and-early-research-development-day\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &amp; Development Day"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=691169"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=691169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=691169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=691169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}